论文部分内容阅读
丙型肝炎(Hepatitis C)是由丙型肝炎病毒感染引起的传染性肝病,更易慢性化,可导致肝脏慢性炎症坏死和纤维化,部分患者可发展为肝硬化甚至原发性肝癌。据世界卫生组织(WHO)统计,全球丙型肝炎慢性感染者约有1.3-1.5亿人,每年新发感染人数达300-400万例,每年大约有50万人死于丙型肝炎导致的终末期肝脏疾病。近年来,由于直接抗病毒药物(DAAs)的出现及在欧美发达国家广泛应用,丙型肝炎的治疗效果取得了长足进步,但仍存在价格昂贵以及病毒耐药等问题,因此,HCV疫苗的研制迫在眉睫。本文重点综述HCV疫苗研制进展。
Hepatitis C is an infectious liver disease caused by Hepatitis C virus infection. It is more likely to become chronic and lead to chronic inflammatory necrosis and fibrosis of the liver. Some patients may develop cirrhosis and even primary liver cancer. According to the World Health Organization (WHO), there are about 130-150 million people infected with chronic hepatitis C virus globally. The annual number of new infections is between 3 and 4 million. Each year, about 500,000 people die of hepatitis C End-stage liver disease. In recent years, due to the emergence of direct antiviral drugs (DAAs) and its widespread application in developed countries in Europe and the United States, great progress has been made in the treatment of hepatitis C, but there are still problems such as being expensive and virus-resistant. Therefore, the development of HCV vaccine Imminent. This article focuses on the development of HCV vaccines.